BiotechTube

Orforglipron + Placebo

Phase 3Recruiting
0 views this week 0 watching⚡ Active🏛️Featured in Big Pharma Pipeline
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Atherosclerosis Cardiovascular Disease

Conditions

Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease

Trial Timeline

Dec 1, 2025 → Aug 1, 2031

NCT ID
NCT07241390

About Orforglipron + Placebo

Orforglipron + Placebo is a phase 3 stage product being developed by Eli Lilly for Atherosclerosis Cardiovascular Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07241390. Target conditions include Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease.

What happened to similar drugs?

13 of 20 similar drugs in Atherosclerosis Cardiovascular Disease were approved

Approved (13) Terminated (3) Active (6)
✅Rosuvastatin + placebo + aspirin + placeboAstraZenecaApproved
✅Rosuvastatin + PlaceboAstraZenecaApproved
✅Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mgAstraZenecaApproved
✅Niacin/simvastatin compared to simvastatin alone at 2 dosesMerckApproved
✅Ezetimibe + PlaceboMerckApproved
✅Simvastatin or Atorvastatin + Enalapril + Aspirin or clopidogrel + RimonabantPfizerApproved
✅AtorvastatinPfizerApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT07241390Phase 3Recruiting
NCT07223593Phase 3Recruiting
NCT07202884Phase 3Recruiting
NCT07153471Phase 3Recruiting
NCT06972472Phase 3Recruiting
NCT06972459Phase 3Recruiting
NCT06993792Phase 3Recruiting
NCT06952530Phase 3Recruiting
NCT06948435Phase 3Recruiting
NCT06948422Phase 3Recruiting
NCT06824051Phase 1Completed
NCT06672939Phase 3Recruiting
NCT06672549Phase 3Recruiting
NCT06649045Phase 3Active
NCT06584916Phase 3Completed
NCT06109311Phase 3Completed
NCT05971940Phase 3Completed
NCT05931380Phase 3Completed
NCT05869903Phase 3Active
NCT05872620Phase 3Completed

Competing Products

20 competing products in Atherosclerosis Cardiovascular Disease

See all competitors
ProductCompanyStageHype Score
Olmesartan medoxomil + PlaceboDaiichi SankyoPhase 3
40
Pactimibe sulfateDaiichi SankyoPhase 2/3
30
PactimibeDaiichi SankyoPhase 2
35
Bempedoic acid + Ezetimibe + Rosuvastatin + AtorvastatinDaiichi SankyoPhase 3
47
Micronized 17B-estradiolJohnson & JohnsonPhase 2/3
38
Rosuvastatin + placebo + aspirin + placeboAstraZenecaApproved
43
Rosuvastatin + PlaceboAstraZenecaApproved
35
rosuvastatin + placeboAstraZenecaPhase 1
29
Rosuvastatin + PlaceboAstraZenecaPhase 1
29
Rosuvastatin + AtorvastatinAstraZenecaPhase 3
40
Rosuvastatin + PlaceboAstraZenecaPhase 3
40
Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mgAstraZenecaApproved
39
Vorapaxar + PlaceboMerckPhase 3
40
Vorapaxar + Placebo + Aspirin + ClopidogrelMerckPhase 2
35
Niacin/simvastatin compared to simvastatin alone at 2 dosesMerckApproved
43
lovastatinMerckPhase 2/3
38
Ezetimibe + PlaceboMerckApproved
43
Vorapaxar + PlaceboMerckPhase 3
32
NiaspanMerckPre-clinical
22
MK0633MerckPhase 2
35